Sonoma Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

9. Significant Customer Concentrations

9. Significant Customer Concentrations	9 Months Ended
Dec. 31, 2013
Risks and Uncertainties [Abstract]
9. Significant Customer Concentrations	For the three months ended December 31, 2013, one customer represented 38%, one customer represented 20%, and one customer represented 14% of net revenue. For the three months ended December 31, 2012, one customer represented 25%, one customer represented 24%, and one customer represented 15% of revenue. For the nine months ended December 31, 2013, one customer represented 37%, one customer represented 25%, and one customer represented 10% of net revenue. For the nine months ended December 31, 2012, one customer represented 27% of revenue. At December 31, 2013, one customer represented 43%, one customer represented 21%, and one customer represented 13% of the net accounts receivable balance. At March 31, 2013, one customer represented 34%, one customer represented 26%, and one customer represented 15% of the net accounts receivable balance.

9. Significant Customer Concentrations

9 Months Ended

Dec. 31, 2013

For the three months ended December 31, 2013, one customer represented 38%, one customer represented 20%, and one customer represented 14% of net revenue. For the three months ended December 31, 2012, one customer represented 25%, one customer represented 24%, and one customer represented 15% of revenue.

For the nine months ended December 31, 2013, one customer represented 37%, one customer represented 25%, and one customer represented 10% of net revenue. For the nine months ended December 31, 2012, one customer represented 27% of revenue.

At December 31, 2013, one customer represented 43%, one customer represented 21%, and one customer represented 13% of the net accounts receivable balance. At March 31, 2013, one customer represented 34%, one customer represented 26%, and one customer represented 15% of the net accounts receivable balance.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References + Details